Chemung Canal Trust Co. Has $621,000 Stock Position in Kenvue Inc. $KVUE

Chemung Canal Trust Co. lessened its holdings in Kenvue Inc. (NYSE:KVUE) by 9.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 29,664 shares of the company’s stock after selling 2,978 shares during the period. Chemung Canal Trust Co.’s holdings in Kenvue were worth $621,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of KVUE. GAMMA Investing LLC lifted its position in shares of Kenvue by 3,092.9% in the first quarter. GAMMA Investing LLC now owns 594,176 shares of the company’s stock worth $14,248,000 after buying an additional 575,567 shares during the last quarter. NBC Securities Inc. raised its stake in shares of Kenvue by 89,208.3% in the 1st quarter. NBC Securities Inc. now owns 10,717 shares of the company’s stock valued at $256,000 after acquiring an additional 10,705 shares in the last quarter. Merit Financial Group LLC raised its stake in shares of Kenvue by 237.8% in the 1st quarter. Merit Financial Group LLC now owns 37,481 shares of the company’s stock valued at $899,000 after acquiring an additional 26,387 shares in the last quarter. RFG Advisory LLC lifted its holdings in Kenvue by 34.5% in the 1st quarter. RFG Advisory LLC now owns 20,386 shares of the company’s stock worth $489,000 after purchasing an additional 5,233 shares during the last quarter. Finally, Butensky & Cohen Financial Security Inc. boosted its position in Kenvue by 1.3% during the first quarter. Butensky & Cohen Financial Security Inc. now owns 207,142 shares of the company’s stock worth $4,967,000 after purchasing an additional 2,718 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

KVUE has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “hold (c)” rating on shares of Kenvue in a research report on Saturday, September 27th. Barclays dropped their target price on shares of Kenvue from $20.00 to $17.00 and set an “equal weight” rating on the stock in a report on Wednesday. Redburn Partners set a $22.00 price target on shares of Kenvue in a report on Friday, September 26th. UBS Group dropped their price objective on Kenvue from $25.00 to $23.00 and set a “neutral” rating on the stock in a research note on Thursday, July 17th. Finally, Rothschild & Co Redburn raised Kenvue from a “neutral” rating to a “buy” rating and cut their price objective for the stock from $22.50 to $22.00 in a research report on Friday, September 26th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $22.46.

Kenvue Stock Up 0.4%

NYSE KVUE opened at $15.80 on Friday. Kenvue Inc. has a twelve month low of $15.47 and a twelve month high of $25.17. The stock has a market cap of $30.31 billion, a PE ratio of 21.34, a PEG ratio of 2.27 and a beta of 0.72. The firm has a 50-day simple moving average of $19.71 and a 200 day simple moving average of $21.57. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The firm had revenue of $3.84 billion for the quarter, compared to analyst estimates of $3.94 billion. During the same period in the previous year, the company posted $0.32 earnings per share. The company’s quarterly revenue was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, research analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were given a $0.2075 dividend. This represents a $0.83 annualized dividend and a yield of 5.3%. This is an increase from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend was Wednesday, August 13th. Kenvue’s dividend payout ratio (DPR) is 112.16%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.